<DOC>
	<DOCNO>NCT00500188</DOCNO>
	<brief_summary>Primary objective 1 . To determine whether induction apoptosis inhibition angiogenesis involve antitumor activity ( Gleevec , Formerly STI-571 ) patient gastrointestinal stromal tumor ( GIST ) assess Positron Emission Tomography ( PET ) scan . 2 . To determine whether dynamic computed tomography ( CT ) , PET scan , molecular histopathologic response GIST tumor patient treat Gleevec predict Disease-Free Survival ( DFS ) time . Secondary objective 1 . To determine disease free survival patient resectable partially resectable gastrointestinal stromal tumor treat Gleevec preoperatively continue 2 year resection disease . 2 . To assess safety tolerability Gleevec give patient GI stromal tumor 3 , 5 , 7 day preoperatively continue postoperatively .</brief_summary>
	<brief_title>Preoperative Postoperative Imatinib Mesylate Study Patients With c-Kit Positive GIST</brief_title>
	<detailed_description>Imatinib mesylate drug may help kill gastrointestinal stromal tumor cell . Around 3 week schedule surgery , PET scan , CT scan two three tablespoon blood collect . These image test do check status disease . These test repeat day schedule surgery . If doctor feel necessary , chest x-ray 2 3 tablespoon blood collect routine test . Women able child must negative blood pregnancy test . Before treatment , also biopsy procedure tumor perform . This biopsy do study effect imatinib mesylate tumor cell . The tissue collect biopsy procedure compare tumor take time surgery . You randomly assign ( toss coin ) one three group . One group begin take imatinib mesylate two time day mouth start 7 day surgery . The second group start take imatinib mesylate 5 day surgery . Participants third group begin take imatinib mesylate 3 day surgery . After surgery , remove tumor study compare tissue collect surgery see effect ( ) imatinib mesylate tumor . All patient continue imatinib mesylate 2 year surgery . You take imatinib mesylate two time day 2 year . If develop side effect study drug , treatment may temporarily stop dose drug change symptom go . If disease get bad experience intolerable side effect , take study doctor discus treatment option . You see physician regularly surgery . Two three tablespoon blood collect month routine test , CT scan do every 3 month . These test help u determine cancer come back . THIS IS AN INVESTIGATIONAL STUDY . Imatinib mesylate FDA approve commercially available . Up 48 participant take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Signed informed consent . 2 . Patients must histologically prove diagnosis primary , locally advanced and/or metastatic GIST complete partial resection plan MDACC sarcoma surgeon . 3 . Patients must immunohistochemical documentation kit expression tumor use DAKO A4502 acceptable antibody . 4 . Patients must least one lesion great 1 cm accurately measure one dimension plain radiograph , CT magnetic resonance imaging ( MRI ) . 5 . Patients must normal organ marrow function ( White blood countWBC great equal 3,000/ul , Absolute neutrophil count ( ANC ) great equal 1500/ul , platelet great equal 100,00/ul , total bilirubin less equal 1.5 * Upper Limits Normal ( ULN ) , aspartate aminotransferase ( AST SGOT ) alanine aminotransferase ( ALT SGPT ) less equal 2.5 * ULN , serum creatinine less equal 1.5 * ULN ) . 6 . Patients must serum glucose &lt; 200 mg/dl prior PET scan . Patients must able lie flat still PET scan . 7 . Patients may uncontrolled medical psychiatric condition would make patient unable tolerate therapy . Patients uncontrolled medical condition psychiatric condition may inform consent grant legal guardian surrogate decision maker . 8 . Patients may prior malignancy past 5 year nonmelanoma skin cancer , cervical cancer situ , malignancy currently clinically significant . 9 . Zubrod performance status 0 3 . 10 . May metastases outside peritoneal cavity . 11 . If patient sign symptom metastasis , appropriate workup occur prior enrollment ( eg , CT head patient central nervous system ( CNS ) symptom ) . 12 . Patients may chemotherapy , radiotherapy , biological therapy investigational drug 3 week prior study . 13 . Women negative pregnancy test within 7 day study open . 14 . Patients must agree use effective contraceptive method . 1 . Prior treatment use Gleevec . 2 . Patients Class III Class IV New York Heart Association congestive heart failure . 3 . Pregnant nursing woman . 4 . Patients take therapeutic dos Coumadin anticoagulation . Coumadin may take dose less equal 1 mg po per day . Patients MAY take low molecular weight heparin .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Gastrointestinal Stromal Tumors</keyword>
	<keyword>GIST</keyword>
	<keyword>Kit expression</keyword>
	<keyword>Resectable</keyword>
	<keyword>Imatinib Mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>STI-571</keyword>
	<keyword>Imatinib</keyword>
	<keyword>NSC-716051</keyword>
</DOC>